GlassScriptPhysician profile
Shweta Gupta
NPI 1376781252
$1,725.10
in general payments reported to CMS, 2019-2025
24 companies · $540 in 2025
The $540 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2021: $20.87 · 2022: $70.76 · 2023: $435 · 2024: $447 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.25 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $340.16 | 2019-2025 | Kadcyla, Phesgo, Perjeta |
| Lilly USA, LLC | $154.51 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Mirati Therapeutics, INC. | $148.51 | 2023-2024 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $140.61 | 2024-2025 | |
| Octapharma USA, INC. | $94.29 | 2023 | Nuwiq |
| Springworks Therapeutics, INC. | $87.58 | 2024-2025 | Ogsiveo |
| Merck Sharp & Dohme LLC | $78.99 | 2024-2025 | Keytruda |
| Gilead Sciences, INC. | $75.15 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $72.91 | 2019-2025 | Opdivo |
| Adaptive Biotechnologies Corporation | $66.59 | 2024-2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $59.01 | 2022-2025 | Lynparza, Enhertu |
| Emd Serono, INC. | $48.21 | 2024-2025 | |
| Celgene Corporation | $43.84 | 2023 | Pomalyst, Reblozyl |
| Pharmacyclics LLC, An Abbvie Company | $42.86 | 2019 | |
| Pfizer INC. | $41.93 | 2019-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $34.64 | 2024 | |
| Genzyme Corporation | $32.42 | 2025 | |
| Amgen INC. | $31.03 | 2023 | |
| Glaxosmithkline, LLC. | $29.00 | 2025 | Jemperli, Zejula |
| Sobi, INC | $27.81 | 2025 | |
| Incyte Corporation | $25.93 | 2025 | Jakafi |
| Astellas Pharma US INC | $20.87 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.96 | 2022 | |
| Pharmaand Gmbh | $10.29 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shweta Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.